SLC4A10: A Promising Drug Target and Biomarker for Chronic Kidney Disease

Target Name: SLC4A10

NCBI ID: G57282

SLC4A10

SLC4A10: A Promising Drug Target and Biomarker for Chronic Kidney Disease

Abstract:
Sodium-driven chloride bicarbonate exchanger (ISO form 1) (SLC4A10) is a protein that plays a crucial role in maintaining homeostasis in the body. It is expressed in many tissues and organs, including the kidneys, and is involved in the regulation of electrolyte balance. SLC4A10 has been identified as a potential drug target and biomarker for chronic kidney disease (CKD). This article reviews the current literature on SLC4A10, including its function, localization, and potential therapeutic applications in the context of CKD.

Introduction:
Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide, with over 50% of the world's population having some form of the disease. The most common cause of CKD is diabetes, which can lead to damage to the glomeruli and interstitial tissues. Other causes of CKD include obesity, physical inactivity, and aging. Symptoms of CKD include proteinuria, edema, decreased urine output, and an increased risk of cardiovascular disease. Treatment options for CKD are limited, and there is a high need for new, effective therapies to slow the progression of the disease and improve outcomes.

SLC4A10: A Key Protein in Homeostasis

Sodium-driven chloride bicarbonate exchanger (ISO form 1) (SLC4A10) is a protein that is expressed in many tissues and organs, including the kidneys. It is involved in the regulation of electrolyte balance and has been identified as a potential drug target and biomarker for CKD. SLC4A10 is a transmembrane protein that consists of two main subunits, SLC4A10A and SLC4A10B. SLC4A10A is the catalytic subunit, responsible for the transfer of chloride ions from the intracellular environment to the extracellular environment, while SLC4A10B is the structural subunit, involved in the regulation of the protein's stability and interactions with other cellular components.

SLC4A10 is expressed in a variety of tissues, including the brain, heart, skeletal muscles, liver, and kidney. It is also expressed in the placenta, which may be a source of the protein in fetal development. SLC4A10 is involved in the regulation of a variety of physiological processes, including electrolyte balance, blood pressure, and acid-base balance. It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway.

In addition to its role in homeostasis, SLC4A10 is also a potential therapeutic target for CKD. SLC4A10 has been shown to be involved in the regulation of cellular processes that are important in the development and progression of CKD, such as inflammation, fibrosis, and autophagy. SLC4A10 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in the regulation of energy metabolism, including the production of reactive oxygen species (ROS).

Potential Therapeutic Applications

SLC4A10 has the potential to be a drug target for a variety of diseases, including CKD. Several studies have shown that SLC4A10 is involved in the regulation of cellular processes that are important in the development and progression of CKD, such as inflammation, fibrosis, and autophagy.

SLC4A10 has been shown to be involved in the regulation of inflammation in CKD. Several studies have shown that SLC4A10 is involved in the regulation of pro-inflammatory

Protein Name: Solute Carrier Family 4 Member 10

Functions: Sodium/bicarbonate cotransporter which plays an important role in regulating intracellular pH (PubMed:18319254). Has been shown to act as a sodium/bicarbonate cotransporter in exchange for intracellular chloride (By similarity). Has also been shown to act as a sodium/biocarbonate cotransporter which does not couple net influx of bicarbonate to net efflux of chloride, with the observed chloride efflux being due to chloride self-exchange (PubMed:18319254). Controls neuronal pH and may contribute to the secretion of cerebrospinal fluid (By similarity). Reduces the excitability of CA1 pyramidal neurons and modulates short-term synaptic plasticity (By similarity). Required in retinal cells to maintain normal pH which is necessary for normal vision (By similarity). In the kidney, likely to mediate bicarbonate reclamation in the apical membrane of the proximal tubules (By similarity)

The "SLC4A10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC4A10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets